Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin

Cancer Research

Volumn 67, Issue 24, 2007, Pages 11630-11639

  Jin, Quanri ^a   Feng, Lei ^a   Behrens, Carmen ^a   Bekele, B Nebiyou ^a   Wistuba, Ignacio I ^a   Hong, Waun Ki ^a   Lee, Ho Young ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6 [4 (2 PIPERIDIN 1 YL ETHOXY)PHENYL] 3 PYRIDIN 4 YLPYRAZOLO[1,5 A]PYRIMIDINE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; DEGUELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; SURVIVIN; TUBERIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CELL GROWTH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MULTIENZYME COMPLEXES; NEOPLASM PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; ROTENONE; TRANSFECTION; UNCOUPLING AGENTS;

EID: 37549005069     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2401     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Spurgers KB, Chari NS, Bohnenstiehl NL, et al. Molecular mediators of cell death in multistep carcinogenesis: a path to targeted therapy. Cell Death Differ 2006;13:1360-70.
3. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20.
4. Colnaghi R, Connell CM, Barrett RM, et al. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006;281:33450-6.
5. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-9.
6. Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003;200:620-6.
7. Vaira V, Lee CW, Goel HL, et al. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 2007;26: 2678-84.
8. Stromberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004; 103:3138-47.
9. Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-93.
10. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-57.
11. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577-90.
12. Hardie DG. The AMP-activated protein kinase pathway - new players upstream and downstream. J Cell Sci 2004;117:5479-87.
13. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003;13:2004-8.
14. Bolster DR, Crozier SJ, Kimball SR, et al. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002; 277:23977-80.
15. D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 2005;280: 39582-93.
16. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000; 19:6341-50.
17. Hahn-Windgassen A, Nogueira V, Chen CC, et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005;280:32081-9.
18. King TD, Song L, Jope RS. AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3. Biochem Pharmacol 2006;71:1637-47.
19. Tzatsos A, Tsichlis PN. Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser794. J Biol Chem. In press 2007.
20. Gerhauser C, Mar W, Lee SK, et al. Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat Med 1995;1:260-6.
21. Chun KH, Kosmeder JW II, Sun S, et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003;95: 291-302.
22. Lee HY, Oh SH, Woo JK, et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 2005;97:1695-9.
23. Udeani GO, Gerhauser C, Thomas CF, et al. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res 1997;57:3424-8.
24. Gills JJ, Kosmeder J II, Moon RC, et al. Effect of deguelin on UVB-induced skin carcinogenesis. J Chemother 2005;17:297-301.
25. Klein-Szanto AJ, Iizasa T, Momiki S, et al. A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc Natl Acad Sci U S A 1992;89:6693-7.
26. Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007;117:730-8.
27. 2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 2005;11: 6065-74.
28. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the lung. In: Travis WD, Brambilla E, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 68-77.
29. Han JY, Oh SH, Morgillo F, et al. Hypoxia-inducible factor 1α and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005;97:1272-86.
30. Lee HY, Moon H, Chun KH, et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst 2004;96:1536-48.
31. Hofmann HS, Simm A, Hammer A, et al. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol 2002; 128:554-60.
32. Tsao AS, McDonnell T, Lam S, et al. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 2003;12:660-4.
33. Lu B, Gonzalez A, Massion PP, et al. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004;91:537-40.
34. Knauer SK, Kramer OH, Knosel T, et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007;21:207-16.
35. Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002; 8:54-60.
36. Ghosh S, Tergaonkar V, Rothlin CV, et al. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-κB activation and cell survival. Cancer Cell 2006; 10:215-26.
37. Tamm I, Richter S, Oltersdorf D, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004;10:3737-44.
38. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001; 108:981-90.
39. Dasgupta P, Kinkade R, Joshi B, et al. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 2006;103:6332-7.
40. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000;60: 2805-9.
41. Xiang R, Mizutani N, Luo Y, et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005;65:553-61.
42. Konno R, Yamakawa H, Utsunomiya H, et al. Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod 2000;6:529-34.
43. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 2003;100:13791-6.
44. Oh SH, Woo JK, Yazici YD, et al. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 2007;99:949-61.
45. Peng XH, Karna P, O'Regan RM, et al. Downregulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol 2007;71:101-11.
46. Hwang JT, Kim YM, Surh YJ, et al. Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer Res 2006;66: 10057-63.
47. He G, Sung YM, Digiovanni J, et al. Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res 2006;66:1873-8.
48. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73.